COST-EFFECTIVENESS ANALYSIS OF CEMIPLIMAB FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CARCINOMA IN SPAIN

被引：0
|
作者：
Sanchez-Marin, J. [1 ]
Leon, L. [2 ]
Sanchez-Hernandez, A. [3 ]
Uria, E. [1 ]
Nieves, D. [1 ]
机构：
[1] Pharmalex, Barcelona, Spain
[2] Complexo Hosp Univ Santiago Compostela SERGAS, Translat Med Oncol Oncomet, Hlth Res Inst Santiago IDIS, Santiago De Compostela, Spain
[3] Consorcio Hosp Prov Castellon, Castellon De La Plana, Spain
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE327
引用
收藏
页码：S118 / S118
页数：1
相关论文
共 50 条
  • [31] A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB FOR PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN PORTUGAL
    Pinheiro, B.
    Silva Miguel, L.
    Alarcao, J.
    Paracha, N.
    Felizzi, F.
    Pereira, C.
    Borges, M.
    VALUE IN HEALTH, 2019, 22 : S450 - S450
  • [32] The cost-effectiveness analysis of EGFR mutation test for management of advanced non-small cell lung cancer in Thailand.
    Siritanadeepun, Tanavadee
    Hanvoravongchai, Piya
    Sriuranpong, Virote
    Parinyanitikul, Napa
    Sitthideatphaiboon, Piyada
    Poovorawan, Nattaya
    Tanasanvimon, Suebpong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer
    Georgieva, M.
    Aguiar, P., Jr.
    Lima, J. P.
    Haaland, B.
    Lopes, G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2148 - S2149
  • [34] A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer
    Nan Qiao
    Ralph Insinga
    Gilberto de Lima Lopes Junior
    John Cook
    Martin Sénécal
    PharmacoEconomics - Open, 2021, 5 : 365 - 383
  • [35] Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer
    Billingham, LJ
    Bathers, S
    Burton, A
    Bryan, S
    Cullen, MH
    LUNG CANCER, 2002, 37 (02) : 219 - 225
  • [36] COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Yang, M. C.
    Tan, E. C. H.
    VALUE IN HEALTH, 2014, 17 (07) : A736 - A736
  • [37] Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
    Yang, Szu-Chun
    Kunst, Natalia
    Gross, Cary P.
    Wang, Jung-Der
    Su, Wu-Chou
    Wang, Shi-Yi
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [38] A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer
    Qiao, Nan
    Insinga, Ralph
    Lopes Junior, Gilberto de Lima
    Cook, John
    Senecal, Martin
    PHARMACOECONOMICS-OPEN, 2021, 5 (03) : 365 - 383
  • [39] Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer
    Georgieva, Mina
    da Silveira Nogueira Lima, Joao P.
    Aguiar, Pedro
    Lopes, Gilberto de Lima, Jr.
    Haaland, Benjamin
    LUNG CANCER, 2018, 124 : 248 - 254
  • [40] COST-EFFECTIVENESS OF TORACOTOMY VERSUS VIDEOTORACOSCOPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER IN STADIUM
    Guevara, G. A.
    Parody, E.
    Aguirre, A. F.
    VALUE IN HEALTH, 2015, 18 (07) : A821 - A821
12345